Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 5Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Ovarian Neoplasms 19Small Cell Lung Carcinoma 9Carcinoma, Ovarian Epithelial 8Fallopian Tube Neoplasms 7Recurrence 6Brain Neoplasms 5Neuroblastoma 4Neoplasms 4Lung Neoplasms 4Medulloblastoma 3Glioma 3Central Nervous System Neoplasms 3Uterine Cervical Neoplasms 2Rhabdoid Tumor 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm Metastasis 2Meningeal Carcinomatosis 2Familial ependymoma 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Astrocytoma 2Unspecified Childhood Solid Tumor, Protocol Specific 1Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Sarcoma 1Rhabdomyosarcoma 1Retinoblastoma 1Optic Nerve Glioma 1Oligodendroglioma 1

Interventions

Temozolomide 52Radiotherapy 24Bevacizumab 23Radiation 10Magnetic Resonance Spectroscopy 7Lomustine 7Carmustine 7Radiosurgery 6Surgical Procedures, Operative 5Irinotecan 5Aminolevulinic Acid 5Radiotherapy, Intensity-Modulated 4Nivolumab 4Ipilimumab 4Erlotinib Hydrochloride 4Cilengitide 4vocimagene amiretrorepvec 3vitespin 3sargramostim 3poly ICLC 3pembrolizumab 3fluoromisonidazole 3carmustine, poliferprosan 20 drug combination 3Vorinostat 3TPI-287 3O(6)-benzylguanine 3Granulocyte-Macrophage Colony-Stimulating Factor 3Flucytosine 3Dynamic Contrast Enhanced Magnetic Resonance Imaging 3Drug Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Glioblastoma × Topotecan × Clear all
NCT00014443 2023-01-09

Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma

Rush University Medical Center

Phase 2 Terminated
5 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡